This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical-devices: Archive
The New Olink Target 48 Neurodegeneration Panel May Boost TMO Stock
by Zacks Equity Research
Thermo Fisher unveils the Olink Target 48 Neurodegeneration panel to accelerate biomarker research in neurodegenerative diseases.
TMOPositive Net Change CAHNegative Net Change MASINegative Net Change PAHCNegative Net Change
medical medical-devices
Should You Continue to Hold Integra Stock in Your Portfolio Now?
by Zacks Equity Research
IART shows strong demand in neurosurgery and Tissue Technologies but faces macro and liquidity challenges.
CAHNegative Net Change IARTNegative Net Change MASINegative Net Change PAHCNegative Net Change
medical medical-devices
ISRG Stock Dips Despite Introducing Real-Time Insights on da Vinci 5
by Zacks Equity Research
Intuitive Surgical unveils real-time surgical insights on its da Vinci 5, enhancing precision, safety, and efficiency with advanced software features.
ISRGPositive Net Change WSTPositive Net Change MEDPNegative Net Change NVSTNegative Net Change
medical medical-devices
Hims & Hers Expands AI and Technology Focus to Advance Digital Care
by Debanjana Dey
HIMS boosts AI investment and appoints a new CTO as it advances personalized, technology-driven digital healthcare at scale.
TDOCPositive Net Change GDRXPositive Net Change HIMSNegative Net Change
medical medical-devices
GEHC Eyes icometrix Buyout to Strengthen Neurology Imaging Portfolio
by Zacks Equity Research
GE HealthCare moves to strengthen its neurology portfolio by acquiring icometrix, aiming to integrate AI-driven brain MRI solutions into its imaging platforms.
WSTPositive Net Change MEDPNegative Net Change NVSTNegative Net Change GEHCNegative Net Change
medical medical-devices
SOLV Strong Q2 Results Signal Momentum: Is the Stock Worth Buying Now?
by Zacks Equity Research
Solventum beats on Q2 earnings, raises guidance, and powers ahead with transformation despite looming tariff headwinds.
BDXPositive Net Change HSICNegative Net Change STEPositive Net Change SOLVPositive Net Change
medical medical-devices
MMSI Stock Falls Despite CE Mark Win for Embosphere in Knee OA Care
by Zacks Equity Research
Merit Medical secures CE Mark for Embosphere, expanding its use in knee osteoarthritis treatment with a minimally invasive alternative.
MMSINegative Net Change WSTPositive Net Change MEDPNegative Net Change NVSTNegative Net Change
medical medical-devices
Should You Buy Pyxis Oncology, Inc. (PYXS) After Golden Cross?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
PYXSPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Howard Hughes Holdings (HHH) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?
HHHPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
ISRG Stock Down More than 13% in 3 Months: How to Play the Stock?
by Indrajit Bandyopadhyay
Intuitive Surgical shares are down 13% in three months as margin pressures weigh on the stock, but strong procedure growth keeps its long-term story intact.
JNJNegative Net Change MDTPositive Net Change ISRGPositive Net Change PRCTPositive Net Change
medical medical-devices
Hologic's Breast Health Rebound in Motion: How to Play the Stock Now?
by Moumi Mondal
HOLX's Breast Health revival, fueled by AI, leadership shifts and product upgrades, is setting up a growth rebound.
DHRPositive Net Change HOLXNegative Net Change GEHCNegative Net Change
medical medical-devices
Hims & Hers Surges 64.1% in 6 Months: How to Play the Stock?
by Debanjana Dey
HIMS accelerates with new men's health launches, global expansion plans and strong subscriber-driven growth, but rising costs strain gross margins.
TDOCPositive Net Change AMWLNegative Net Change HIMSNegative Net Change
medical medical-devices
Exact Sciences Launches Cancerguard MCED Blood Test, Stock Climbs
by Zacks Equity Research
EXAS introduces Cancerguard, a blood test that detects more than 50 cancers, sending shares up after its U.S. debut.
MASINegative Net Change PAHCNegative Net Change EXASNegative Net Change NVSTNegative Net Change
medical medical-devices
Should You Add IDEXX Stock to Your Portfolio Right Now?
by Zacks Equity Research
IDXX shows strong CAG Diagnostics growth, cloud software momentum and global expansion but faces solvency and macro risks.
MASINegative Net Change IDXXPositive Net Change PAHCNegative Net Change NVSTNegative Net Change
medical medical-devices
NVIDIA, AI & Quantum Leaders Drive Health Tech: 2 Stocks to Buy
by Urmimala Biswas
Butterfly Network and Omnicell emerge as standout health tech stocks as AI and quantum breakthroughs reshape diagnostics and medication management.
IBMPositive Net Change NVDANegative Net Change OMCLPositive Net Change PLTRNegative Net Change BFLYNegative Net Change
artificial-intelligence cloud-computing medical medical-devices smart-health tech-stocks
Pulse Biosciences Gets FDA IDE Nod for Atrial Fibrillation Study
by Zacks Equity Research
PLSE wins FDA IDE approval for its NANOCLAMP AF study, advancing nsPFA tech as a novel option in atrial fibrillation surgery.
WSTPositive Net Change MEDPNegative Net Change PLSEPositive Net Change NVSTNegative Net Change
medical medical-devices
Here's Why You Should Retain OPKO Health Stock in Your Portfolio
by Zacks Equity Research
OPK benefits from RAYALDEE momentum, strategic deals and advancing trials amid stiff competition and dependence risks.
WSTPositive Net Change OPKPositive Net Change MEDPNegative Net Change NVSTNegative Net Change
medical medical-devices
After Golden Cross, nCino (NCNO)'s Technical Outlook is Bright
by Zacks Equity Research
Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?
NCNONegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Reasons to Add West Pharmaceutical Stock to Your Portfolio Now
by Zacks Equity Research
WST rides on GLP-1 demand and Annex 1 expansion, but margins face pressure from pricing and tariff headwinds.
WSTPositive Net Change INGNNegative Net Change MEDPNegative Net Change GEHCNegative Net Change
medical medical-devices
CVS Health Makes Headway in Stabilizing Aetna: What's Driving It?
by Moumi Mondal
CVS makes progress in stabilizing Aetna with leadership, risk management and operational changes.
UNHNegative Net Change CVSPositive Net Change CNCNegative Net Change
medical medical-devices
Reasons to Retain Avanos Medical Stock in Your Portfolio Now
by Zacks Equity Research
AVNS's solid Q2 performance, strong product demand, and strategic transformation support growth amid tariff and FX headwinds.
BSXNegative Net Change WSTPositive Net Change MEDPNegative Net Change AVNSNegative Net Change
medical medical-devices
Hologic's 2025 Outlook Improves on Strong Q3, Easing Tariff Headwinds
by Moumi Mondal
HOLX lifts its 2025 revenue and EPS outlook on Q3 strength, tariff relief, and growth across Breast Health and GYN Surgical.
BDXPositive Net Change HOLXNegative Net Change QGENPositive Net Change
medical medical-devices
Should You Continue to Hold EXAS Stock in Your Portfolio?
by Zacks Equity Research
Exact Sciences sees growth in Cologuard and Oncotype DX, but rising costs and tough competition weigh on EXAS shares.
MASINegative Net Change PAHCNegative Net Change EXASNegative Net Change NVSTNegative Net Change
medical medical-devices
Harley-Davidson (HOG)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?
HOGPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Trip.com (TCOM) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
TCOMPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines